The evidence that functional TP53 could be considered as a putative biomarker for selecting cases that might benefit from Notch3 inhibition was also confirmed by combining Notch3 inhibition with the tyrosine kinase inhibitor brivanib in different human cancer cells [56]. Here, NOTCH3 is linked to cancer.